You searched for joep lange - Page 19 of 20

01 Jan Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients

Posted at 00:00h

Authored by: Autar Reshma Saskia, Wit Ferdinand W. N. M., Sankote Jongkol, Sutthichom Duanghathai, Kimenai Elly, Hassink Elly, Hill Andrew, Cooper David A., Phanuphak Praphan, Lange Joep M. A., Burger David M., Ruxrungtham Kiat In: AIDS 21(12), 2007, p.1535-1539 http://www.ncbi.nlm.nih.gov/pubmed/17630547

01 Jan Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells

Posted at 00:00h

Authored by: Sankatsing Sanjay U. C., Cornelissen Marion, Kloosterboer Nico, Crommentuyn Kristel M. L., Bosch Tessa M., Mul Frederik P., Jurriaans Suzanne, Huitema Alwin D. R., Beijnen Jos H., Lange Joep M. A., Prins Jan M., Schuitemaker HannekeIn: AIDS RESEARCH AND HUMAN RETROVIRUSES 23(1), 2007,...

01 Jan Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen

Posted at 00:00h

Authored by: Autar Reshma S., Boyd Mark A., Wit Ferdinand W. M. N., Ruxrungthams Kiat, Sankote Jongkol, Lange Joep, Cooper David A., Phanuphak Praphan, Burger David M., Reiss Peter In: ANTIVIRAL THERAPY 12(8), 2007, p.1265-1271 http://www.ncbi.nlm.nih.gov/pubmed/18240866

01 Jan Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen

Posted at 00:00h

Authored by: Scherpbier Henriette J., Bekker Vincent, Pajkrt Dasja, Jurriaans Suzanne, Lange Joep M. A., Kuijpers Taco W.In: PEDIATRICS 119(3), 2007, p.e705-e715http://www.ncbi.nlm.nih.gov/pubmed/17308244

01 Jan CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater

Posted at 00:00h

Authored by: Gras Luuk, Kesselring Anouk M., Griffin James T., van Sighem Ard I., Fraser Christophe, Ghani Azra C., Miedema Frank, Reiss Peter, Lange Joep M. A., de Wolf FrankIn: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 45(2), 2007, p.183-192http://www.ncbi.nlm.nih.gov/pubmed/17414934

01 Jan Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries

Posted at 00:00h

Authored by: Sow Papa S., Otieno Leander F., Bissagnene Emmanuel, Kityo Cissy, Bennink Ruurd, Clevenbergh Philippe, Wit Ferdinand W. N. M., Waalberg Esther, Rinke de Wit Tobias F., Lange Joep M.In: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 44(3), 2007, p.262-267http://www.ncbi.nlm.nih.gov/pubmed/17146376

01 Jan Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens

Posted at 00:00h

Authored by: Kerr Stephen J., Duncombe Chris, Avihingsanon Anchalee, Ananworanich Jintanat, Boyd Mark, Sopa Bunruan, Medtech B., Chuenyam Theshinee, Cooper David A., Lange Joep M. A., Phanuphak Praphan, Ruxrungtham KiatIn: JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PHYSICIANS IN AIDS CARE (CHICAGO, ILL. 6(1), 2007, p.36-46http://www.ncbi.nlm.nih.gov/pubmed/17329503

01 Jan Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response

Posted at 00:00h

Authored by: van Leth Frank, Wit Ferdinand W., Lange Joep M. In: BMC MEDICAL RESEARCH METHODOLOGY 7, 2007, p.14- http://www.ncbi.nlm.nih.gov/pubmed/17335563

01 Jan The development of artificial neural networks to predict virological response to combination HIV therapy

Posted at 00:00h

Authored by: Larder Brendan, Wang Dechao, Revell Andrew, Montaner Julio, Harrigan Richard, de Wolf Frank, Lange Joep, Wegner Scott, Ruiz Lidia, Pérez-Elías Maria Jésus, Emery Sean, Gatell Jose, Monforte Antonella D.’Arminio, Torti Carlo, Zazzi Maurizio, Lane CliffordIn: ANTIVIRAL THERAPY 12(1), 2007, p.15-24http://www.ncbi.nlm.nih.gov/pubmed/17503743

01 Jan A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor

Posted at 00:00h

Authored by: Vermeulen Joost N., Meijer Dirk K. F., Over Jan, Lange Joep M. A., Proost Johannes H., Bakker Hester I., Beljaars Leonie, Wit Ferdinand W. N. M., Prins Jan M.In: ANTIVIRAL THERAPY 12(2), 2007, p.273-278http://www.ncbi.nlm.nih.gov/pubmed/17503670

Search

01 Jan Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients

01 Jan Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells

01 Jan Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen

01 Jan Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen

01 Jan CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater

01 Jan Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries

01 Jan Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens

01 Jan Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response

01 Jan The development of artificial neural networks to predict virological response to combination HIV therapy

01 Jan A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor

Contact

QUICK LINKS